Stephenson Cancer Center | Strategic Alliance Partners

Latest from Stephenson Cancer Center


Moore Voices Excitement With VS-6766 Plus Defactinib in Ovarian Cancer

October 07, 2021

Dr. Moore discusses the basis for studying the combination of VS-6766 and defactinib in recurrent low-grade serous ovarian cancer, data that has been generated with the combination from the phase 1/2 FRAME trial, and the potential role for the combination in clinical practice.

Dr. Moore on the Role of Mirvetuximab Soravtansine in Ovarian Cancer

March 04, 2020

Kathleen Moore, MD, director, Oklahoma TSET Phase I Clinical Trials Program, and associate professor, Section of Gynecologic Oncology, Jim and Christy Everest Endowed Chair in Cancer Research, director, Gynecologic Oncology Fellowship Program, associate director of Clinical Research, and medical director of the Clinical Trials Office, at Stephenson Cancer Center, discusses the role of mirvetuximab soravtansine in platinum-resistant ovarian cancer.

OncLive Welcomes Stephenson Cancer Center to Strategic Alliance Partnership Program

January 12, 2015

OncLive® and Stephenson Cancer Center, the only comprehensive academic cancer center in Oklahoma, have become partners in raising the standard of cancer care through OncLive's Strategic Alliance Partnership program, OncLive announced.